Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of 1 of the following: * Hematologic cancer, including any of the following: * Chronic lymphocytic leukemia or small lymphocytic lymphoma meeting any of the following criteria: * Relapsed within 1 year after prior fludarabine phosphate-containing regimens OR not a candidate to receive such therapy due to comorbidities or allergies * Received prior anti-CD52 monoclonal antibody therapy OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy) * Has documentation of disease-associated symptoms, rapid progression of disease, or other indications for treatment * B- or T-cell prolymphocytic leukemia meeting any of the following criteria: * Relapsed within 1 year after prior fludarabine phosphate- or alkylating agent-containing regimens OR not a candidate to receive such therapy due to comorbidities or allergies * Relapsed within 1 year after prior anti-CD20 monoclonal antibody therapy OR ineligible to receive such therapy (for patients with CD20-positive disease) * Received prior anti-CD52 monoclonal antibody therapy OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy) * Lymphoplasmacytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, or follicular lymphoma meeting any of the following criteria: * Relapsed within 1 year after prior fludarabine phosphate- or alkyl…